[Postmenopausal osteoporosis from the viewpoint of the gynecologist].
Prophylaxis of postmenopausal osteoporosis is of major importance if estrogen replacement therapy is considered. Assessment of clinical symptoms, (standardized) x-ray analysis, and bone densitometry contribute to the final diagnosis. Incidence of osteoporotic fractures is rising due to alterations in life style and dietary habits. One out of three to four women eventually suffer from osteoporosis in the European countries, United States and Japan. Prevention of postmenopausal osteoporosis is achieved by adequate estrogen replacement therapy carried out for years, maintaining peripheral estradiol concentrations of 220 pmol/l. Doses of 2 mg estradiol or 0.625 mg of conjugated estrogen or 50-100 micrograms percutaneous estradiol/day are equally effective for prevention. The additional administration of a progestogen may be of specific value to increase the antiresorptive effect of estrogens. We distinguish between estrogen replacement in a cyclic or continuous way combined with a sequential or continuous progestogen in women with intact uterus.
Dören
M
M
Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde B, Westfälischen Wilhelms-Universität Münster.
Schneider
H P
HP
D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000209:etiology / Q000517:prevention & control*; D045167:Progesterone Congeners / Q000008:administration & dosage; D012307:Risk Factors
D045167:Progesterone Congeners
Die postmenopausale Osteoporose aus der Sicht des Frauenarztes.